PT-141

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin agonist with a well-defined investigative research record distinguishing it from most peptides in its class. Structurally it derives from Melanotan II but differs in that the N-terminal acetyl group is absent, a modification that shifts the receptor selectivity profile meaningfully toward MC4R while preserving MC3R activity—and substantially reduces the MC1R-mediated pigmentation effects seen with MT-2.

PT-141's MC4R selectivity is the basis for its most studied biological effects. The MC4R is expressed centrally in hypothalamic and limbic structures involved in arousal and motivation circuits, and this central mechanism differentiates PT-141 mechanistically from PDE5 inhibitors, which act peripherally on vascular smooth muscle. In investigative Phase II/III trials, PT-141 demonstrated statistically significant effects on desire-related endpoints in both male and female cohorts—a finding that makes it a reference compound for central arousal pathway research.

APEX 100 supplies PT-141 as ≥99% HPLC-verified lyophilized powder (MW ~1,025.17 Da, C₅₀H₆₈N₁₄O₁₀), with mass spectrometry confirmation of identity and a full Certificate of Analysis included.

For research and laboratory use only. Not for human consumption.

<

p style="